We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
CommentaryFree Access

Why do young adults living with HIV perform poorly on combined antiretroviral therapy (CART)? – a Zimbabwean perspective

    Munyaradzi Madhombiro

    *Author for correspondence:

    E-mail Address: munyarad@buffalo.edu

    University of Zimbabwe, College of Health Sciences, Department of Psychiatry, Parirenyatwa Group of Health Sciences, Mazowe Street, Belgravia, Harare, Zimbabwe

    ,
    Raymond Cha

    University at Buffalo, The State University of New York, School of Pharmacy & Pharmaceutical Sciences, Buffalo, NY 14414, USA

    ,
    Joshua Sawyer

    University at Buffalo, The State University of New York, School of Pharmacy & Pharmaceutical Sciences, Buffalo, NY 14414, USA

    ,
    Sarahmona Przybyla

    University at Buffalo, The State University of New York, School of Public Health, Buffalo, NY 14214, USA

    ,
    Gale Burstein

    Commissioner of Health Erie County, Health 95 Franklin St, Room 910, Buffalo, NY 14202, USA

    &
    Gene D Morse

    University at Buffalo, The State University of New York, Pharmacy Practice (Medicine, Pediatrics), SUNY Global Health Institute, UB Center for Integrated Global Biomedical Sciences, Drug Development Core, UB Clinical & Translational Science Institute, Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, NY 14203, 716-881-7464

    Published Online:https://doi.org/10.2217/fvl-2019-0020
    Free first page

    References

    • 1 Judd A, Lodwick R, Noguera-Julian A et al. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe . HIV Med. 18(3), 171–180 (2017).
    • 2 Lee S, Hazra R. Achieving 90-90-90 in paediatric HIV: adolescence as the touchstone for transition success. J. Int. AIDS Soc. 18(Suppl. 6), 20257 (2015).
    • 3 Machado DM, Succi RC, Turato ER. Transitioning adolescents living with HIV/AIDS to adult-oriented health care: an emerging challenge. J. Pediatr. 86(6), 465–472 (2010).
    • 4 Vreeman RC, Scanlon ML, McHenry MS et al. The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. J. Int. AIDS Soc. 18(Suppl. 6), 20258 (2015).
    • 5 Arrive E, Dicko F, Amghar H et al. HIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa. PLoS ONE 7(3), e33690 (2012).
    • 6 Gamarel KE, Brown L, Kahler CW et al. Prevalence and correlates of substance use among youth living with HIV in clinical settings. Drug Alcohol Depend. 169, 11–18 (2016).
    • 7 Maskew M, Fox MP, Evans D et al. Insights into adherence among a cohort of adolescents aged 12–20years in South Africa: reported barriers to antiretroviral treatment. AIDS Res. Treat. 2016, 1–12 (2016).
    • 8 Willis N, Mavhu W, Wogrin C et al. Understanding the experience and manifestation of depression in adolescents living with HIV in Harare, Zimbabwe. PLoS ONE 13(1), e0190423 (2018).
    • 9 Vreeman RC, McCoy BM, Lee S. Mental health challenges among adolescents living with HIV. J. Int. AIDS Soc. 20(Suppl. 3), 21497 (2017).
    • 10 Lowenthal ED, Bakeera-Kitaka S, Marukutira T et al. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. Lancet Infect. Dis. 14(7), 627–639 (2014).
    • 11 Laughton B, Cornell M, Boivin M et al. Neurodevelopment in perinatally HIV-infected children: a concern for adolescence. J. Int. AIDS Soc. 16, 18603 (2013).
    • 12 Ayano G, Solomon M, Abraha M. A systematic review and meta-analysis of epidemiology of depression in people living with HIV in east Africa. BMC Psychiatry 18(1), 254 (2018).
    • 13 Bigna JJ, Tounouga DN, Kenne AM et al. Epidemiology of depressive disorders in people living with HIV in Africa: a systematic review and meta-analysis: Burden of depression in HIV in Africa. Gen. Hosp. Psychiatry 57, 13–22 (2018).
    • 14 Barroso J, Burrage J, Carlson J et al. Salivary cortisol values in HIV-positive people. J. Assoc. Nurses AIDS Care 17(3), 29–36 (2006).
    • 15 Richter L, Makusha T, Komarek A et al. Exploring the impact of childhood abuse on HIV social and attitudinal factors among adults with and without this history in sub-saharan africa: findings from NIMH project accept (HPTN 043). AIDS Behav. 20(4), 737–745 (2016).
    • 16 Rowe C, Santos GM, McFarland W et al. Prevalence and correlates of substance use among trans female youth ages 16–24 years in the San Francisco Bay Area. Drug Alcohol Depend. 147, 160–166 (2015).
    • 17 Ahmed-Leitao F, Spies G, van den Heuvel L et al. Hippocampal and amygdala volumes in adults with posttraumatic stress disorder secondary to childhood abuse or maltreatment: a systematic review. Psychiatry Res. Neuroimaging 256, 33–43 (2016).
    • 18 Zimbabwe Church, Health Ministry Launches Anti-Drug Campaign (2019). www.voanews.com/a/zimbabwe-youth-substance-abuse/4735119.html. •Alcohol and substance use is a rising problem in all of Africa, and also in Zimbabwe, and it has become one of our top three diagnoses.
    • 19 Georgsson G. Neuropathologic aspects of lentiviral infections. Ann. NY Acad. Sci. 724, 50–67 (1994).
    • 20 Persidsky Y, Poluektova L. Immune privilege and HIV-1 persistence in the CNS. Immunol. Rev. 213, 180–194 (2006).
    • 21 Hazleton JE, Berman JW, Eugenin EA. Novel mechanisms of central nervous system damage in HIV infection. HIV AIDS 2, 39–49 (2010).
    • 22 Williams DW, Veenstra M, Gaskill PJ et al. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr. HIV Res. 12(2), 85–96 (2014).
    • 23 Lamers SL, Fogel GB, Nolan DJ et al. HIV-associated neuropathogenesis: a systems biology perspective for modeling and therapy. Biosystems 119, 53–61 (2014).
    • 24 Brack-Werner R, Bell JE. Replication of HIV-1 in human astrocytes. NeuroAids 2(8), 1–22 (1999).
    • 25 Li GH, Henderson L, Nath A. Astrocytes as an HIV reservoir: mechanism of HIV infection. Curr. HIV Res. 14(5), 373–381 (2016).
    • 26 Eugenin EA, Clements JE, Zink MC et al. Human immunodeficiency virus infection of human astrocytes disrupts blood–brain barrier integrity by a gap junction-dependent mechanism. J. Neurosci. 31(26), 9456–9465 (2011).
    • 27 Yu F, Hao Y, Zhao H et al. Distinct mitochondrial disturbance in CD4+T and CD8+T cells from hiv-infected patients. J. Acquir. Immune Defic. Syndr. 74(2), 206–212 (2017).
    • 28 Saylor D, Dickens AM, Sacktor N et al. HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat. Rev. Neurol. 12(5), 309 (2016).
    • 29 Joska JA, Fincham DS, Stein DJ et al. Clinical correlates of HIV-associated neurocognitive disorders in South Africa. AIDS Behav. 14(2), 371–378 (2010).
    • 30 Ortega M, Heaps JM, Joska J et al. HIV clades B and C are associated with reduced brain volumetrics. J. Neurovirol. 19(5), 479–487 (2013).
    • 31 UNAIDS ‘AIDSinfo’ (2019). www.unaids.org/en/resources/fact-sheet.